275 related articles for article (PubMed ID: 26641242)
1. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
3. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
5. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
[TBL] [Abstract][Full Text] [Related]
7. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
8. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
9. Primary sclerosing cholangitis: updates in diagnosis and therapy.
Portincasa P; Vacca M; Moschetta A; Petruzzelli M; Palasciano G; van Erpecum KJ; van Berge-Henegouwen GP
World J Gastroenterol; 2005 Jan; 11(1):7-16. PubMed ID: 15609388
[TBL] [Abstract][Full Text] [Related]
10. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Williamson KD; Chapman RW
Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary sclerosing cholangitis.
Floreani A; De Martin S
Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
[TBL] [Abstract][Full Text] [Related]
12. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
13. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
14. Novel developments in IBD-related sclerosing cholangitis.
Ponsioen CY
Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925
[TBL] [Abstract][Full Text] [Related]
15. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
16. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
17. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
19. Current treatments of primary sclerosing cholangitis.
Vacca M; Krawczyk M; Petruzzelli M; Sasso RC; van Erpecum KJ; Palasciano G; van Berge-Henegouwen GP; Moschetta A; Portincasa P
Curr Med Chem; 2007; 14(19):2081-94. PubMed ID: 17691949
[TBL] [Abstract][Full Text] [Related]
20. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
